H.I.G. Capital's Strategic Acquisition of ITH Group Limited
H.I.G. Capital, a prominent alternative investment firm managing around $70 billion in assets, has successfully acquired ITH Group Limited, a leading provider of aseptic pharmaceutical compounding services in the UK. This acquisition marks a significant investment aimed at enhancing ITH's capacity and expertise in providing specialized medications.
About ITH Group Limited
Founded in 2008, ITH Group specializes in creating customized injectable medications tailored to patients with unique medical requirements. Their services primarily focus on chemotherapy, total parenteral nutrition, and central intravenous additive services, positioning the company as a market leader in these critical healthcare areas. They also run a digital pharmacy that plays a vital role in serving both private and NHS patients, ensuring they have access to essential medications.
Commitment to Growth and Innovation
As part of this acquisition, H.I.G. aims to leverage ITH's existing management, with founders Adam Bloom as CEO and Karen Hamling as COO, continuing to steer the revolution within the company. H.I.G. is committed to nurturing ITH's legacy of growth and innovation, looking to enhance their production capabilities and build even stronger relationships within the healthcare sector.
Partnership with a Vision
Adam Bloom, the CEO, expressed enthusiasm about welcoming H.I.G. as they venture into the next phase of ITH's growth. Since its establishment, ITH has focused on investing in its workforce and refining patient-focused services to support both the public NHS services and private medical care. This partnership is seen as a transformative move that will allow ITH to expand its offerings, advance its capabilities in critical compounding, and improve pharmacy services further.
Industry Recognition and Future Aspirations
Both Adam Bloom and John Harper, Managing Director at H.I.G., highlighted the significance of H.I.G. stepping in as a strategic partner. John Harper outlined that H.I.G. is excited about enhancing ITH’s reputation for delivering compounded pharmaceuticals reliably to NHS and private customers in a market with increasing demand, pointing towards a promising future.
Trust and Reputation in Healthcare
Gordon Cameron, the non-executive Chairman of ITH, praised the founders for establishing a company that provides essential pharmaceutical services in the UK health system. He affirmed H.I.G.’s commitment to contribute to the business's growth trajectory, emphasizing reliable and high-quality service delivery.
About H.I.G. Capital
Founded in 1993, H.I.G. is renowned for its operationally focused approach, investing in both equity and debt across various middle-market companies globally. Their portfolio includes over 400 companies with substantial collective revenues, showcasing their impactful presence in diverse sectors, particularly in healthcare.
Contact Information for H.I.G. Capital
For more information, interested parties can reach out to John Harper, Managing Director at H.I.G. Capital, located at 10 Grosvenor Street, 2nd Floor, London, W1K 4QB, United Kingdom, or contact through the provided phone number.
Frequently Asked Questions
What is H.I.G. Capital known for?
H.I.G. Capital specializes in alternative investments, managing around $70 billion across various industries, especially in mid-market companies.
What services does ITH Group provide?
ITH Group offers aseptic pharmaceutical compounding services, particularly focusing on chemotherapy and other specialized medical needs.
Who are the key people at ITH Group?
Adam Bloom serves as the CEO and Karen Hamling as COO, both of whom will continue to lead the company following the acquisition.
How does the acquisition enhance ITH’s capabilities?
The acquisition will support ITH’s growth by enhancing production capacity and expanding its range of services, benefitting both NHS and private healthcare sectors.
When was ITH Group founded?
ITH Group was founded in 2008, focusing on specialized compounding services for the healthcare industry.
